Review Article

Secondary Metabolites with Antioxidant Activities for the Putative Treatment of Amyotrophic Lateral Sclerosis (ALS): “Experimental Evidences”

Jamire M. Silva,1,2 Michelangelo S. C. Nobre,1,2 Sonaly L. Albino,2,3 Lucas L. Lócio,2,3 Agnis P. S. Nascimento,2,4 Luciana Scotti,5 Marcus T. Scotti,5 João A. Oshiro-Junior,3 Maria C. A. Lima,1 Francisco J. B. Mendonça-Junior6, and Ricardo O. Moura2,3,4

1Postgraduate Program in Pharmaceutical Sciences-PPGCF, Department of Pharmacy, Federal University of Pernambuco, 50670-901 Recife PB, Brazil
2Drug Development and Synthesis Laboratory, Department of Pharmacy, State University of Paraíba, 58429-500 Campina Grande PB, Brazil
3Postgraduate Program in Pharmaceutical Sciences-PPGCF, Department of Pharmacy, State University of Paraíba, 58429-500 Campina Grande PB, Brazil
4Graduate Program in Chemistry-PPGQ, Department of Chemistry, State University of Paraíba, 58429-500 Campina Grande PB, Brazil
5Laboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products, Federal University of Paraíba, João Pessoa PB, Brazil
6Laboratory of Synthesis and Drug Delivery, Department of Biological Sciences, State University of Paraíba, 58071-160 João Pessoa PB, Brazil

Correspondence should be addressed to Francisco J. B. Mendonça-Junior; xicolouco@gmail.com

Received 24 April 2020; Revised 2 October 2020; Accepted 4 October 2020; Published 24 November 2020

Academic Editor: Bruno Meloni

Copyright © 2020 Jamire M. Silva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disorder that is characterized by progressive loss of the upper and lower motor neurons at the spinal or bulbar level. Oxidative stress (OS) associated with mitochondrial dysfunction and the deterioration of the electron transport chain are factors that contribute to neurodegeneration and perform a potential role in the pathogenesis of ALS. Natural antioxidant molecules have been proposed as an alternative form of treatment for the prevention of age-related neurological diseases, in which ALS is included. Researches support that regulations in cellular reduction/oxidation (redox) processes are being increasingly implicated in this disease, and antioxidant drugs are aimed at a promising pathway to treatment. Among the strategies used for obtaining new drugs, we can highlight the isolation of secondary metabolite compounds from natural sources that, along with semisynthetic derivatives, correspond to approximately 40% of the drugs found on the market. Among these compounds, we emphasize oxygenated and nitrogenous compounds, such as flavonoids, coumarins, and alkaloids, in addition to the fatty acids, that already stand out in the literature for their antioxidant properties, consisting in a part of the diets of millions of people worldwide. Therefore, this review is aimed at presenting and summarizing the main articles published within the last years, which represent the therapeutic potential of antioxidant compounds of natural origin for the treatment of ALS.

1. Introduction

Amyotrophic lateral sclerosis (ALS), also known as Charcot’s or Lou Gehrig’s disease, is a progressive and ultimately fatal neurodegenerative disorder characterized by affecting cortical and spinal motor neurons that control the voluntary motions of muscles [1, 2]. It is currently classified according to the mode of the emergence of the pathology in familial
(10% of cases), also referred as FALS, inherited in an autosomal dominant, autosomal recessive, or X-linked manner, and sporadic (90% of cases), also known as sALS, which is not genetically inherited [3]. Both types of ALS share the most common symptoms, which manifests as muscle weakness, twitching, and cramping, subsequently leading to the impairment of muscles. In the most advanced stages, the symptoms extend to dyspnea, dysphagia, paralysis, and eventual death from respiratory failure within 3 to 5 years after symptom onset [4, 5].

ALS is the most common motor neuron disease, even though the mechanism evolved in the neurodegenerative dysfunction that leads to motor neurons’ loss is not entirely known [6, 7]. Histopathological data shows reduction in neuron size, loss and atrophy of nerve fibers, vacuolization, large empty spaces near neurons, and sponge-like appearance caused by spongiosis [8].

Its incidence is associated with increased age, as it onsets mostly in adults between 50–65 years, and is slightly more prevalent in males than females, with a ratio of approximately 1.6:1 [4, 9]. The majority of the epidemiological studies have been conducted in Europe, in which the incidence of ALS is 2–3 people per year per 100,000 general population. Furthermore, an increase in the prevalence of ALS to 8.58 cases per 100,000 inhabitants in the United Kingdom population is expected by the year of 2020 [5, 10].

Multiple pathophysiological mechanisms and cellular dysfunctions are involved as possible causative factors in the disease. Among these, the following stand out: accumulation of reactive oxygen species, mitochondrial dysfunction, neuroinflammation, alterations on RNA processing, glutamate excitotoxicity, apoptosis, protein misfolding and aggregation, autophagy, impaired axonal transport and neurofilament aggregation, and endoplasmic reticulum stress. Moreover, environmental factors have shown to contribute to the pathogenicity, such as alcohol, tobacco, physical activity, chemical exposure and metals, and exposure to radiation [1, 10–12].

The oxidative stress is highly correlated with the development and progression of the neurodegenerative processes in ALS. Changes in the homeostatic balance of ROS production are particularly associated with mutant forms of the antioxidant enzyme SOD1 (encodes for copper/zinc ion-binding superoxide dismutase), which is reported to be the most common causative factor for ALS. Over 150 different mutations have been described in different parts of the enzyme, which include G93A (glycine 93 changed to alanine), H46R (histidine at codon 46 changed to arginine), and A4V (alanine at codon 4 changed to valine). This particular enzyme is responsible for catalyzing the conversion of superoxide (O2·) into hydrogen peroxide and oxygen. Its mutation provokes a structural instability that promotes enzyme misfolding, and consequent formation of cytotoxic protein aggregates alone or with other proteins. Consequently, there is a loss of enzyme activity and an increase in the production of ROS that results in deterioration in the regulation of vital cell processes and mitochondrial dysfunction [4, 13–16].

There is no cure for ALS, and current drug treatment is limited since only two drugs are approved by the Food and Drug Administration for the treatment of the disease: Riluzole, a neuroprotective drug that blocks glutamatergic neurotransmission and, more recently, the antioxidant drug Edaravone. These assist in delaying the progression of the disease, extending life expectancy by 2-3 months [2, 17].

Therefore, the obtainment of new drugs, capable of effectively fulfilling the gap in the therapeutic arsenal in order to assist in the treatment and in the decrease of the disease’s progression, presents itself as a priority. Among the strategies used for obtaining new drugs, we can highlight the isolation of secondary metabolite compounds from natural products that, along with semisynthetic derivatives, correspond to approximately 40% of the drugs found on the market [18].

Focusing on the influence of ROS for the onset and progression of the disease, the interest in natural compounds with antioxidant potential has become increasing. According to epidemiological studies focused on neurodegenerative diseases, it was observed that there is a significant difference in the incidence of such diseases among ethnic groups with different eating habits, recording that the diet rich in antioxidants is related to a decrease in the incidence rate. Thus, different types of compounds with antioxidant properties can be highlighted, such as the following: polyphenols, which provide protection against ROS and modulate metabolic cascades [19, 20]; carotenoids, which perform antioxidant and neutralizing activities against ROS [19–22]; antioxidant vitamins such as vitamins C and E, among others [13, 14, 23]. Hence, this review is aimed at presenting and summarizing the main articles published within the last years, which represent the therapeutic potential of antioxidant compounds of natural origin for the treatment of ALS. In this sense, the keywords “antioxidant activity,” “amyotrophic lateral sclerosis,” “natural products,” and “secondary metabolites,” among others, were included in the search into the databases “ScienceDirect,” “PubMed,” “Periódicos Capes,” “Clinical Trials,” “Web of Science,” and “Google Acadêmico,” during the period of March 14 to April 10 2020.

2. Secondary Metabolites with Potential Antioxidant Action and Their Possible Applications for ALS

2.1. Alkaloids. Alkaloids comprise the largest group of nitrogen compounds, characterized by containing one or more nitrogen atoms within a heterocyclic ring. Over 12,000 compounds are known to be provided by a variety of sources such as animals, bacteria, plants, and fungi [24, 25]. Figure 1 presents the chemical structure of some well-known alkaloids, such as nicotine (1), morphine (2), and caffeine (3). Nitrogen, oxygen, carbon, and hydrogen are the chemical elements that constitute its basic formula, so that its molecular weight varies between 100 and 900 g mol⁻¹. This class of compounds has revealed to be one of the most promising secondary metabolites for ALS treatment due to their diverse mechanism of action, which can collaborate to prevent the disease evolution [26–28].

It has been suggested that the increase of extracellular glutamate occurs mainly due to an anomaly in glutamate
Figure 1: Chemical structure of the well-known alkaloids (nicotine (1), morphin (2), and caffeine (3)), such as those used in preclinical antioxidant studies (8-methoxy-N-methylflindersine (4), zanthodioline (5), alternamid A (6), alternamid B (7), alternamine A (8), hydroxytyrosol (9), formamide (10), alternamine B (11), uridine (12), mitraphylline (13), isomitraphylline (14), iraqine (15), and kareemine (16)).
transporter EAAT2/GLT-1 and leads to ALS. Harmine, a beta-carboline alkaloid, may act by activating EAAT2/GLT-1 gene expression increasing the cellular uptake of glutamate [29]. The indirect mechanism was suggested by the use of alkaloids with commercial drug Riluzole, aiming to block the increased levels of P-glycoprotein in the blood-brain barrier (BBB) [30]. In this sense, Lopez and Martinez-Luis showed that polyaromatic alkaloids from prosobranch molusk (Lamellaria sp.) restrain P-gp, demonstrating an increased cellular uptake to different drugs in resistant cell line [31]. However, in this review, we will highlight the benefits of its mechanism of action as antioxidants, since alkaloids have the ability to convert free radical species in inactive substances [32, 33]. Thus, researches have explored the advantages of employing alkaloids with this purpose, alone or included in a pharmaceutical form and from several sources [34–37].

For example, in order to evaluate the antioxidant activity of two quinoline isolated alkaloids from Zanthoxylum rhetsa root bark, Zohora and collaborators showed through DPPH assay that the compounds 8-methoxy-N-methylflindersine (4) and zanthodiolide (5) (Figure 1) presented free radical scavenging activity (IC50 in μg/mL) of 71.18 ± 1.74 and 101.90 ± 5.24, respectively, revealing potent antioxidant activity [38].

Alternanthera littoralis P. Beauv. is a tree common in tropical, subtropical, and temperate regions. Koolen et al. isolated seven chemical alkaloids from the aerial parts of this plant, which include two known alkaloids, hydroxytyrosol (9) and uridine (12), and five new alkaloids, namely, alternamide A (6), alternamide B (7), alternamine A (8), N-(3,4-dihydroxyphenethyl) formamide (10), and alternamine B (11) (Figure 1). The biological evaluations showed the high antioxidant free radical scavenging effect of the ethanolic extract containing alkaloids alternamide B (1.10 relative Trolox equivalent—RTE), alternamide A (0.85 RTE), and alternamine B (0.65 RTE) in relation to positive control quercetin (5.62 RTE) [39].

Azevedo et al. studied the alkaloids mitraphylline (13) and isomitraphylline (14) (Figure 1) obtained from extracts of the aqueous leaf extract (ALE) from Uncaria tomentosa which present high phenolic content (153.51 μg gallic acid equivalents per milligram extract). The ALE in vitro antioxidant activity investigation, performed using DPPH, ABTS, and ferric reducing antioxidant power (FRAP) assays, obtained values of IC50 = 10.68 ± 0.64 μg mL−1, 2.15 ± 0.29 mmol Trolox/mg AA and extract, and 2.9 ± 0.15 mMFeSO4/mg AA and extract, respectively, presenting a moderate activity [40].

Aiming to obtain new alkaloids, Aldulaimi and collaborators isolated from Alphonsea cylindrical King two novel isoquinoline alkaloids, namely, iraqine (15) and kareemine (16) (Figure 1). In vitro antioxidant activity was performed, and the results showed IC50 values of 48.77 and 101.66 μg mL−1, respectively. In this same test, five additional known alkaloids were tested and among them, O-methylmoschatoline (144.15 μg/mL) was better than kareemine [41].

Nevertheless, despite of examples above, researching for papers about this matter, using “antioxidant activity” and “alkaloids” as keywords on the Scholar, with range of last 5 years, it is possible to found 822 papers that cite these terms in the abstract and/or title [42]. When the term “ALS” is added, no articles are found and similar results are observed in other databases (Web of Science, Pubmed, and Science-Direct). These works always present alkaloids obtained from different sources and evaluate their biocompatibility and antioxidant activity in vitro using different methods [43, 44]. The association with ALS always happens in a generalized way because one treatment option to neurodegenerative diseases is using this approach [45].

The lack of studies in the literature performing specific preclinical or clinical tests for ALS and no therapy consolidate to alkaloids despite advantages can be by two main problems, not to easy standardization in batch-to-batch reproducibility and scale-up [46]. For these reasons, the use of isolated alkaloid molecules can circumvent these drawbacks. Another possibility is alkaloids-loaded in nanoscale systems to develop new formulation in terms of tissue/organ targeting and BBB penetration as shown in literature [47, 48].

Finally, alkaloids can slow down ALS by three hypothetical mechanisms of action, as mentioned above. Several studies evidenced satisfactory results in terms of antioxidant activity; thus, clinical trials (phase I) are necessary in order to better understand the previously mentioned mechanisms and advance this treatment proposal to improve patients’ life quality.

2.2. Flavonoids. Flavonoids are phenolic compounds derived from the aromatic amino acids phenylalanine and tyrosine, which are widely found in plants. Its structure consists of a flavin nucleus (17) containing 15 carbon atoms arranged in three rings (C6-C3-C6), labeled as A, B, and C, as illustrated in Figure 2. These compounds have a broad pharmacological spectrum, in which their antioxidant and anti-inflammatory activity are mainly associated with the fight against neurodegenerative diseases such as ALS [49].

It is known that processes such as oxidative stress, neuroinflammation, and neural apoptosis collaborate with ALS progression; in this sense, Winter et. al. evaluated the effects of strawberry extract enriched with anthocyanin (18) (Figure 2) in mice with ALS model (G93ASOD1 mutation), as this class of flavonoids has antioxidant, anti-inflammatory, and antiapoptotic activity established in previous studies [50–52]. The trials showed that at a dose of 2 mg/kg/day, guinea pigs suffered a marked delay of approximately 17 days at the onset of the disease, in addition to an increase in life expectancy of approximately 11 days. Histological analysis exhibited a significant reduction in spinal cord injury when compared to mutant guinea pigs not treated with the extract. For that reason, this study emphasizes that anthocyanins have therapeutic potential for this disease and can evolve to more complex pharmacological tests [53].

There are reports in the literature suggesting that the mutation in superoxide dismutase (SOD1) at position 85 of glycine and arginine is a fundamental cause for the onset of ALS. Taking advantage of the antioxidant activity of the
flavonoids kaempferida (19) and kaempferol (20) (Figure 2), the study performed by Srinivasan and Rajasekaranb evaluated through molecular docking their aggregation affinity towards SOD1. Kaempferol portrayed stronger hydrophobic interactions with the target in comparison to kaempferida, thus qualifying it as a possible prototype for the design of new drugs for the treatment of ALS [54].

Ueda and collaborators also proved the action of kaempferida and kaempferol, extracted from Brazilian green propolis, as a possible alternative for the treatment and prevention of ALS. In this study, kaempferida (15 μM) and kaempferol (3.0 μM) were tested against Na2+ cells (superoxide induced) with mutant SOD1. The results showed significant inhibition of mutant SOD1, as well as in Western blot analysis, which showed that kaempferol induced autophagy through the protein kinase activated by AMP, suggesting this as a probable mechanism for neuroprotection and emphasizing this compound as a good therapeutic alternative on the treatment of ALS [55].

A flavonoid known as fisetin (21) (Figure 2), a natural antioxidant, already presented several benefits in some degenerative diseases such as Alzheimer’s and Parkinson’s. Therefore, Wang et al. performed in vitro assays on mutant cells (hSOD1G85R and hSOD1G93A) and in vivo assays with hSOD1 transgenic mice in order to evaluate the efficacy of the compound to SOD1 associated with ALS. Treatment with fisetin improved motor impairment, prolonged life span, and confirmed the neuroprotective antioxidant effects, proposing this flavonoid as a strong drug candidate with therapeutic value for the treatment of ALS [56].

Studies in mice revealed that the first steps in the development of ALS may comprehend the increased presence of SOD1 monomers and their aggregation to motor neurons. In this perspective, Ip and collaborators carried out tests in silico with a library of 4,400 drugs and natural compounds that were coupled in the SOD1 dimer. Between these compounds, seven with best results were tested for aggregation and splitting of SOD1 induced by hydrogen peroxide in vitro at concentrations ranging from 20 μM to 100 μM. Compound 22 (Figure 2) revealed that quercetin-3-β-D-glucoside presented one of the best results, and for that, it may be a potential therapeutic inhibitor of misfolding and aggregation of SOD1 and, therefore, can delay clinical symptoms of ALS [57].

The use of Panax ginseng for the alternative treatment of ALS is recurrent, but without scientific proof, these effects may be related to the increase in the expression of the growth factor for cells of the nervous system and high antioxidant activity. For these reasons, Jiang et al. studied the effects of ginseng extract, rich in flavonoids, at doses of 40 and 80 mg/kg in B6SJL-TgN (SOD1G93A) transgenic mice. Results showed a delay in the appearance of diseases’ signs and increase in survival [58], pointing out the potential of this root and possible mechanism action.

Korkmaza et al. observed that the chronic administration of 5 mg/kg of flavonoid 7,8-dihydroxyflavone (23) (Figure 2), generally found in the plants Godmania aesculifolia and Tri-dax procumbens, in mice with ALS (SOD1G93A) by up to 105 days caused a significant improvement in motor deficits. This result is believed to be associated with the compound’s
ability to cross the blood-brain barrier and exercise neuroprotective activity therefore can decrease the clinical manifestations of the disease [59].

As previously mentioned, the formation of poorly folded protein aggregates inside or outside neural cells is one of the causes of neurodegenerative diseases, such as ALS. In this sense, Joshi and collaborators presented, through in vitro studies with Cos-7 cells in immunofluorescence staining assay with primary antibodies of E6-AP and Hsp70, that at a concentration of 15 μg/mL, mycenet flavonoid (24) (Figure 2) is capable to eliminate or suppress the aggregation of different proteins and reduce the inclusion of folded proteins and leading to a decrease in the symptoms of muscle paralysis [60].

Excessive neuronal stimulation of glutamate leads to a large influx of Ca2+ which, when accumulated in mitochondria, triggers an increase in the production of reactive oxygen species for the formation of oxygen free radicals, just as this excitation leads to the activation of caspase3, which seem to be involved in the etiology of many neurodegenerative disorders, such as ALS. In this context, Shimmyo et al., through in vivo studies with mice induced by glutamate and in vitro tests with neuronal cells, showed that myricetin 24 (Figure 2) inhibited the glutamate-induced excitotoxicity by three routes: reduction of intracellular calcium through the phosphorylation of NMDAR (N-methyl D-aspartate receptor), inhibition of free oxygen radicals, and inhibition of caspase-3 [61].

Aluminum has been associated with several neurological diseases, including Alzheimer’s disease, Parkinson’s disease, and ALS; it is suggested that this neurotoxicity may be associated with the fact that aluminum is capable of generating reactive oxygen species (ROS) [60]. In this perspective, Sharma et al. [62] evaluated the antioxidant activity of quercetin (25) (Figure 2), at a dose of 10 mg/kg body weight/day in mice whose oxidative stress was induced by aluminum (10 mg/kg of body weight/day). The results revealed that quercetin decreased neuronal apoptosis and decreased the production of free radicals, in addition to obstructing neurodegenerative histological changes induced by aluminum.

Zhuang et al. analyzed through mass spectrometry and molecular docking the noncovalent interactions between SOD1 and selected flavonoid compounds, such as quercetin, rutin, naringin, and hesperidin, among others. The study is aimed at identifying which compound has a more prominent capacity to inhibit the aggregation of the apo-SOD1 complex. Through these techniques, the results showed that naringin (26) (Figure 2) presented better aggregation inhibition profile, being considered as an interesting compound for the treatment of ALS [63].

As mentioned in the literature, glutamate toxicity is a major contributor to the appearance of neurodegenerative diseases such as ALS and Alzheimer’s disease. Hence, Elmann and collaborators [64] isolated the sesquiterpene lactone achilleolid A and the flavonoid 3,5,4′-trihydroxy-6,7,3′-trimethoxyflavone (27) (Figure 2) from the Achillea fragrantissima plant and tested in Na2+ cells of neuroblastoma of mice intoxicated with glutamate. The results show that the compounds protected astrocytes from cell death induced by oxidative stress and inhibited microglia activation, demonstrating its significant protective effect. In this sense, we highlight the importance of flavonoids as a therapeutic potential tool against the decrease in the time of onset of symptoms and the increased survival of patients with ALS, whether by antioxidant, neuroanti-inflammatory, and antiprotein aggregation mechanisms.

In silico and in vivo tests of the cited studies demonstrated that extracts enriched with flavonoids, as well as their isolated, may act in the treatment of ALS by different mechanisms of action, such as decreased spinal cord injury, SOD1 inhibition, inhibition of motor neuron aggregation, inhibition caspase3, and decrease reactive oxygen species. These compounds may cause a delay in the appearance of the disease’s signs and decrease the clinical manifestations. Therefore, by evaluating the toxicity of these compounds and establishing a therapeutic dose, they could potentially be qualified to undergo more advanced pharmacological tests, such as clinical trials.

2.3. Coumarins. Coumarins are another class of secondary metabolites implemented in the literature as promising molecules due to their results against neurodegenerative diseases such as ALS. Based on these facts, Mogana et al. tested the antioxidant capacity in vitro of scopoletin (28) isolated from Canarium patentinervium (Figure 3), starting from chloroform extract and purification by silica gel chromatography using the hydrogen atom transfer (HAT) and simple electronic transfer (SET) method. This coumarin presented strong antioxidant potential (EC50 191.51 ± 0.01 μM), demonstrating its ability to act in diseases caused by oxidative stress [65].

In vitro studies for DPPH, hydroxyl, and ABTS radical scavenging activity carried out by Kumar et al. to determine the antioxidant capacity of substances present in fenugreek seed extract (Trigonella foenum-graecum), such as trigocoumarin (29) (Figure 3), were performed. The antioxidant activity of the extract was expressed in IC50 and showed its efficiency in reducing DPPH free radicals, being able to reduce them by 50% at a concentration of 395 μg/mL ($R^2 = 0.9712$) [66].

Oxidative stress was induced in NSC34 motor neurons of rats by Barber and collaborators in the presence and absence of several compounds. Among them, the coumarin esculentin (30) (Figure 3) was the only one of the studied compounds capable of directly buffering the radicals, promoting protective effects for cells. This article does not present the form of obtainment of these compounds [67].

Hasnat and collaborators presented results for inhibition of acetylcholinesterase, as well as in vitro and in vivo antioxidant activity of Ganoderma lucidum that grows in germinated brown rice (GLBR), in which coumarin (31) (Figure 3) is presented as the fourth most predominant compound between the thirteen identified by HPLC analysis of the GLBR extract. In vitro results revealed the occurrence of inhibition of peroxidation induced in brain cells of rats by Fe2+. However, in in vivo results, no significant variations
could be observed when doses of 100 mg/kg were administered in the treatment group [68].

Li and Seeram identified the presence of seven lignans, as well as two coumarins isolated from the butanol extract of the maple syrup (MS-BuOH), being identified as scopoletin and fraxetin (32) (Figure 3). These coumarins were evaluated for their antioxidant activity and obtained IC$_{50}$ values of 68.2 ± 31.2 and 46.5 ± 3.6 μg/mL, respectively. Therefore, these compounds better result in comparison to the seven isolated lignans (values ranging between 101.5 ± 5.9 and 1335.9 ± 47.6 μg/mL) and stilbenes contained in sugar fraction of maple syrup (>2600 μg/mL). Moreover, fraxetin also showed a better result when compared to vitamin C (IC$_{50}$ = 58.6 ± 10.7 μg/mL) [69].

Glutamatergic excessive transmission is associated with several neurodegenerative diseases such as ALS. In order to analyze the antioxidant and neurodegenerative capacity of the seed extract of Amburana cearenses, Pereira and collaborators promoted studies in PC12 cell cultures which were induced by glutamate excitotoxicity. Among the isolated compounds, methyl-3-coumarin (33) was identified (Figure 3). In the isolate containing mainly coumarins, including compound 33, promoted, after 24 h, a reduction of 17% in death induced by glutamate, in addition to inducing neuroprotection in 1000 μg/mL [70].

To test the ability to inhibit oxidative stress from the extract of Angelicae dahuricae radix, which presents furanocoumarin as a secondary metabolite, Moon and colleagues examined its effect on reducing the level of ROS in BV2 cells activated by lipopolysaccharides (LPS). It was observed a significant decrease in ROS levels at the concentrations of 10 and 50 μg/mL. In vivo tests were performed using a dose of 100 mg/kg administered orally to rats during 14 days. The results indicated the extract’s neuroprotective effect after spinal cord injury. In this way, the extract has a possible neuroprotective capacity for diseases such as ALS, mainly due to the decrease in cytokine levels when damage to BV2 cells is inferred [71].

A plant of the same genus, Angelicae gigas, was evaluated for its antioxidative effect directed to neurodegenerative diseases by Park and collaborators, where the presence of coumarins in this plant has been identified in previous works published by Ryu et al. [72]. In vitro tests on DPPH and determination of the reducing capacity demonstrated that
the ethanol extract showed an EE$_{50}$ of 31.47 ± 0.68 mg/mL in the elimination of DPPH. The ethanol extract also showed strong antioxidant activity with an IC$_{50}$ of 43.22 ± 1.67 μg/mL, demonstrating to be more effective in comparison to the aqueous and methanolic extracts, and to the positive control α-tocopherol (68.64 ± 5.47 μg/mL). The initiation and propagation of free radicals in the body can be related to transition metals in which elements such as iron and copper act as powerful catalysts in oxidation reactions. Complementing the tests, metal chelating activity was carried out, which consists of adding different concentrations of the extract, methanol, and FeCl$_3$. For the ethanol extract, an accentuated binding capacity with Fe$_{2+}$ was verified [73].

The effects of *Caragana turfanensis* on neuroinflammation inhibition were evaluated by Song et al. Among the 36 compounds present in the extract, a new coumarin, caraganolide A (34), was observed (Figure 3). The evaluation of each compound was performed on LPS-induced BV2 cells, and caraganolide A demonstrated an IC$_{50}$ of 1.01 ± 1.57 μg/mL, portraying the best activity among all isolated compounds, including in comparison to the positive control (minocycline) of 9.07 ± 0.86 μg/mL [74].

From the extract of aerial parts from *Daucus diaeulis asch*, Morgan and collaborators were able to isolate psoralen (35) and isopsoralen (36), among other compounds (Figure 3). *In vitro* antioxidant activity of these coumarins demonstrated that the elimination of peroxy radicals and the reducing capacity were inferior to the other components of this extract; however, the inhibition of soluble epoxide hydrolase (sEH) by psoralen was favorable, indicating that this compound can act improving the antioxidant defense mechanism, thus being considered a promising compound for diseases such as ALS [75].

Varier et al. performed molecular docking, using AutoDock tools 1.5.6 program and the MGL tools 1.5.6 package, to predict the inhibitory capacity of esculin and hinokitol. In the target monooxidase b, esculin (37) (Figure 3) obtained a more favorable binding affinity, with free energy result of -9.6 Kcal/mol, while the cocrystallized ligand levodopa and hinokitol (38) presented binding energies of -7.7 Kcal/mol and -7.2 Kcal/mol, respectively. For all six evaluated different targets, esculin exhibited the best results in comparison to the aforementioned ligands. Monooxidase B is found in the external mitochondrial membrane, whose dysfunction of this organelle may be associated with common neurodegenerative diseases such as ALS and Alzheimer’s disease [76].

In neurodegenerative diseases such as ALS, compounds that activate signal-regulated kinase phosphorylation (ERK) and element response-binding protein (CREB) are considered as possible neuroprotective agents. Based on this information, Nakamura et al. tested phosphorylation capacity in human A172 cells of felopterin (39) and auraptene (40) isolated from citrus fruits (Figure 3). Both coumarins promoted an activation of ERK and CREB, indicating that the coumarin ring is a possible pharmacophore responsible for activating the neuroprotective effect on the central nervous system [77].

In general, there is an improvement in coping with neurodegenerative diseases such as ALS through the use of isolated coumarins or plant extracts containing them. The results were promising when performed in *silico*, in vitro, and experimentally in *vivo*, revealing its antioxidant effect, prolongation of the programmed death of neural cells, and neuroprotection, beyond the reduction of free radicals.

Most coumarins from natural products could potentially be tested for antioxidant activity, reduction of DPPH, inhibition of induced peroxidation, reduction of glutathione-induced death, and induction of neuroprotection. In general, there is an improvement in dealing with neurodegenerative diseases, such as ALS, through the use of isolated coumarins or plant extracts containing them. The results were promising when performed in *silico*, in vitro, and experimentally in *vivo*, revealing its antioxidant effect, prolongation of the programmed death of neural cells, and neuroprotection, beyond the reduction of free radicals.

2.4. Other Metabolites. In addition to the secondary metabolites present in natural products with antioxidant action already mentioned for the treatment of ALS, it is also common the presence of other metabolites in extracts or fractions of extracts present in leaves, fruits, and roots, as well as in other natural products such as fungi and algae [78–80]. From here, we will present the presence and antioxidant mechanisms of tannins, terpenoids, lignans, quinones, saponins, methylxanthines, glucosinolates, and fatty acids directed to the treatment of ALS.

2.5. Tannins. Tannins are secondary polyphenolic plant metabolites commonly found in extracts from a wide variety of plants [81, 82]. Studies of extracts of several plants containing tannins have already reported their biological activity for the treatment of various diseases, such as neurodegenerative diseases, diabetes, lung infections, rheumatism, and kidney diseases, among others [83, 84].

In this perspective, Auddy and collaborators evaluated through *in vitro* and *in vivo* tests, in an unprecedented way, the toxicity and the effect of eliminating radicals with ethanolic and aqueous extracts of three plants commonly used in Indian medicine: *Sida cordifolia*, *Evolvulus alsinoides*, and *Cynodon dactylon*. The results demonstrated that the water infusion of the three plants (up to 1 mg/mL) did not show toxic effects on the PC12 cell line in the MTT tests. As for the verification of antioxidant effects, it was shown that in the ABTS test, the Ethanolic extract of *S. cordifolia* presented a better result, with an IC$_{50}$ of 16.07 μg/mL, followed by *E. alsinoides* and *C. dactylon*, with IC$_{50}$ values of 33.39 μg/mL and 78.62 μg/mL, respectively. As for water infusions, the IC$_{50}$ values were, respectively: 172.25 μg/mL for *E. alsinoides*, 273.64 μg/mL for *C. dactylon*, and 342.82 μg/mL for *S. cordifolia*. In the results of lipid peroxidation (TBARS), the water infusion of *E. alsinoides* demonstrated the best result out of the three infusions with an IC$_{50}$ of 89.23 μg/mL. *In vivo* studies have not shown significant results, and the author attributes the experimental model as being ineffective due to the high, rapid, and extensive degradation of the antioxidant inside the body. The results were promising for the continuity of tests and verification of activity in neurodegenerative diseases [85].
Banerjee et al. reported an "in vitro" study that evaluated the antioxidant activity of black plum peel and juice extract scientifically known as Syzygium cumini of the myrtaceae family. The antioxidant activities of the aqueous extracts were verified for hydroxyl radicals, superoxide radicals, and stable free radicals 1,1-diphenyl-2-picryl-hydrazil (DPPH). The IC50 values for the fruit peel were 468 μg/mL, 260 μg/mL, and 168 μg/mL, respectively. Thus, it can be said that the antioxidant activity of S. cumini has significant antioxidant activity. The author attributes this activity to the presence of tannins in the extracts and S. cumini is traditionally used to treat various diseases in Asia. The elimination of superoxide radicals, hydroxyl radicals, and nitric oxide radicals with the aqueous extract of the fruit peel of S. cumini has been confirmed in previous studies to evaluate the antioxidant activity of black plum peel and juice extract scientifically known as Syzygium cumini. 

Another study was carried out by Hamamcioglu and collaborators, in which the evaluation of the potential of the neuroprotective effect of PC12 dPC12 cell effects as well as the antimutagenic and antigenotoxic effects of the species of the plant Glaucoma acutidentatum of the papaveraceae family was carried out. The methanolic extract, at a concentration of 500 μg/mL, showed better results for cell damage caused by H2O2, with values between 80 and 90% of neuroprotection, in comparison to the aqueous extract that presented a rate between 65 and 75%. Another important data demonstrated in the same study is concerning the neurtax index, which is strongly linked to the neuroprotective effect. The higher the value, the better the neuroprotective result as it indicates neural regeneration. It was found that in the presence of only H2O2, neurtax index concentration dropped to 50.7 ± 0.4 μM, while the control untreated cells presented a value of 80.3 ± 0.3 μM and the extracts (methanolic and aqueous), in a concentration of 500 μg/mL, exhibited values of 78.8 ± 0.5 μM and 78.2 ± 0.3 μM, respectively. Furthermore, the extracts showed antimutagenic activity (75.0 and 74.8% inhibition) and antigenotoxic activity. This is a pioneering study for antigenotoxic activity. The results demonstrate strong candidates for the treatment of multiple degenerative diseases, including ALS.

The studies presented above with extracts containing tannins in the treatment of ALS demonstrate the lack of in-depth studies, considering that they do not perform in vivo experiments, therefore limited to in vitro studies, and,...
consequently, there are no subsequent preclinical tests and specific clinical trials for ALS. Possibly this continuity of the experiments is linked to the isolation and quantification of the compounds, considering that the majority of the studies did not present gas chromatography techniques.

2.6. Terpenoids. Terpenoids are terpenic compounds that have undergone oxidation. Many studies have been reported with the use of terpenoids in the treatment of diseases [95–97]. One of these studies was carried out by Kiaei and collaborators through the evaluation of the neurodegenerative activities of celastrol (41) (Figure 4), a triterpenoid, isolated from a Chinese plant *Tripterygium wilfordii* of the family *Celastraceae*. In this study, the neuroprotective effects were examined in the G93A SOD1 transgenic mice model for ALS. Studies have shown that the treatment with celastrol significantly improved motor function, delaying ALS symptoms, and also causing a decrease in mice’s weight. Another relevant result was the increase in survival of the G93A mice treated with celastrol, registering 9.4% and 13% at the dosages of 2 mg/kg/day and 8 mg/kg/day, respectively. Moreover, an increase of 30% of the neuronal concentration in the lumbar spine suggests a protective effect. Histological analysis revealed a reduction in TNF-α, GFAP immunoreactivity. Thus, celastrol can be a promising therapeutic agent for the treatment of ALS [98].

In *silico* and *in vivo* evaluations of phytochemicals present in the root extract of the *Asparagus adscendens* (AAE) plant of the *Liliaceae* family were carried out by Pahwa and Goel, aiming to evaluate the nontoxic, antiamnesic, and antioxidative activities. Prediction of Activity Spectra for Substances (PASS) and Pharmexpert were used for *in silico* studies. *In vivo* studies of antiamnesic activity were assessed by scopolamine induction. Finally, nontropic activity was assessed by evaluating the effect of the extract of AAE against antioxidant enzymes on the cortex and hippocampus of mice and acetylcholinesterase. The extracts showed, in addition to other secondary metabolites, the presence of terpenoids. The results in *silico* pointed to a significant decrease in memory loss that was proven by *in vivo* studies. Besides, the AAE extract considerably reduced the levels of oxidative stress in the cortex and hippocampus of mice [99].

Lee et al. investigated the neuroprotective effects of a sesquiterpenoid, ECN (7β-(3-ethylcis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranone) 42) (Figure 4) obtained from *Tussilago farfara* sprout, from the *Asteraceae* family, mediated by Nrf2 (nuclear factor erythroid 2) against oxidative stress in the PC12 cell line, as well as the potential of ECN to activate Nrf2 inducing OH−, also observing the protective effects of ECN (10 μM) in an experimental model of animals with neurodegeneration. The results demonstrated a protective effect against H2O2 and 6-hydroxydopamine (6-OHDA) with 91.8 ± 6.6% and 87.9 ± 1.7% inhibition in the concentration of 500 μM of H2O2 and 250 μM of 6-OHDA, respectively. The ECN also showed good results in the positive regulation of ARE-luciferase activity (cell line designed to monitor the induction of antioxidant response elements), as well as in the induction of Nrf2 and OH− mRNA expression. The results also suggested an interaction between ECN and Keap1 modifying the cysteine thiol of Nrf2, causing a positive regulation of OH−. Furthermore, the administration of ECN improved dopaminergic and motor neuronal damage [100].

2.7. Lignans. Lignans are a group of phytochemicals, which are produced by oxidative dimerization of two phenylpropanoid units [101]. Studies related to the use of plant extracts containing lignans have also been reported in the literature for the treatment of neurodegenerative diseases [102, 103] mainly by the mechanism of peroxidation dismutase-SOD1. In one of these reports, Lahaie-Collins et al. evaluated sesamine (43) (Figure 5), a lignan isolated from sesame seed (*Sesamum indicum L*) and bark of *fagara* plants, for neuroprotective, antioxidant, and anti-inflammatory effects on neuronal cells PC12. The compound 1-methyl-phenylpyridine (MPP+) was used as an oxidative damage inducer. The results showed that in picomolar doses (10−11 M), sesamine protected the PC12 neuronal cells from oxidative stress, attenuating by up to 60% the cell death caused by MPP+, in addition to reducing the production of reactive oxygen species. Further results revealed an increase in the production of SOD proteins, as well as a reduction in catalase. Sesamine showed potential in preventing neurodegenerative diseases [104].

Mei et al. isolated 12 lignans from the fruit of the *Broussonetia papyrifera* plant, among which 9 were unpublished. The ethanolic extracts of each lignan were evaluated for its antioxidant activities via MTT and DPPH in PC12 neuronal cells induced by H2O2 and also for the capability of eliminating DPPH radicals. The results showed that all ethanolic extracts were efficient in antioxidant activities, reducing the action of H2O2 in the CP12 cell line. Compounds 44, 45, 46, 47, and 48 (Figure 5) demonstrated DPPH radical scavenging activity with IC50 values of 236.8 μM, 156.3 μM, 273.9 μM, 281.1 μM, and 60.9 μM, respectively, with H2O2 concentrations ranging from 0.16 to 100 μM. Lignan 48 showed the best antioxidant activity. Subsequent studies may apply these lignans for pharmacotherapeutic treatments of ALS and additional neurodegenerative diseases [105].

Sesamine (Figure 5), as reported previously, was also the object of the study of Shimoyoshi et al. They examined the possibility of sesamine affecting the cognitive decline in mice accelerated by senescence (SAMP10). Analytical methods showed changes in oxidative stress related to age in reactive brain carbonyl species (CRs) in mice treated with sesamine. The results showed that mice treated with sesamine obtained better results in tasks of avoidance and forced swimming with aging. Oxidative stress in the cerebral cortex and liver showed a reduction in mice treated with lignan. These results suggest that sesamine prevents brain dysfunction by antioxidant activity [106].

2.8. Quinones. Similar to the other secondary metabolites, quinones present in extracts have been reported in studies looking for ALS treatments and different neurodegenerative diseases [107–109].
One of these reports, presented by Lu et al., demonstrated the antioxidant effects of ethanolic extracts from the roots of the *Rheum officinale ball* plant of the *Polygonaceae* family, popularly known as rhubarb. Phytochemical analysis of the extracts demonstrated the presence of anthraquinones (emodine 49) and dianthraquinones (aloe-emodine 50) (Figure 6), in addition to other constituents. Rhubarb extract considerably decreased the number of neurons with condensed and fragmented DNA, especially at a concentration of 10 \( \mu \text{g/mL} \) (at concentrations 2 and 5 \( \mu \text{g/mL} \) the results were inferior). The study showed a protective role for rhubarb extract against cell oxidation, which may bring significant results in further studies in the treatment of ALS and other neurodegenerative diseases [109].

Vegás-Hernández and collaborators evaluated the antioxidant effects of rapanone (51) (Figure 6), a natural benzoquinone isolated from the *Myrsine* plant, against the chelation, iron removal activity, and protective potential against damage induced by tert-butyl hydroperoxide in mitochondria. The results showed the formation of complexes with irons II and III, oxidation of iron II, and peroxide radicals, inhibiting Fenton-Haber-Weiss reactions, effectively demonstrating the protective effect against oxidative stress at concentrations of 50 and 300 \( \mu \text{M} \). The results demonstrate the protective potential of rapanone against mitochondrial lipid peroxidation with IC\(_{50}\) 10.33 \( \pm \) 1.29 at 50 \( \mu \text{M} \) values better than the positive glycol-bis(2-aminoethyl ether)-\(N,\text{N}'\)-tetraacetic acid (EGTA) IC\(_{50}\) 15.47 \( \pm \) 2.01 \( \mu \text{M} \) at 200 \( \mu \text{M} \). Thus, rapanona appears with pharmacological potential in the treatment of diseases that occur oxidative stress such as neurodegenerative diseases [110].

Studies with terpenoids, lignans, and quinones are more limited in the literature; however they exhibit greater depth of studies aimed at treating ALS. Unlike studies with tannins, these three metabolites, despite the few studies found, have advanced to *in vivo* studies, presenting significant results in different pathways. Few studies have reported the isolation of the main compound and do not report the extraction methodology transparently. Finally, despite having been carried out *in vivo*, the studies have not yet been reported or evaluated in clinical tests. It may be related to difficulties in isolation, since the extractive methods were not well understood in the study.

### 2.9. Saponins

The classic definition of saponins is based on its surface activity and its detergent properties, forming stable
foams in water. Saponin is a class of glycosidic compounds that can be classified as steroidal saponins and triterpenoid saponins, which can form colloidal solutions that foam in water, like soap, if the mixture is stirred. Saponins can be found in the roots and leaves of plants and present antimicrobial, antibacterial, antiviral, anticancer, and antioxidants activities, in addition to its ability to stimulate the formation of collagen, a protein that plays a role in the healing process of wounds [111–113].

Many saponins have been reported for neuroprotection purposes, including madecassoside (52) [114–117], ginsenoside (53) [118–120], and astragaloside IV (54) [121] (Figure 7). Saponin’s neuroprotection property is not correlated to a single process, but to a spectrum of independent and related processes, which promotes its ability to regenerate the neural network directly promoting cell survival, improving neurite growth, and recovering the activities of axons and synapses. These metabolites can also prevent neuron malfunctions by changing levels of neurotransmitters, axons and synapses. These metabolites can also prevent neuron malfunctions by changing levels of neurotransmitters.

In a model of ALS using a type of lipopolysaccharide-induced rats (LPS), two different doses of madecassoside were tested, 61.1 ± 11.0 and 185.6 ± 18.7 mg/kg/day, respectively. Compared to the control group (mice without madecassoside treatment), madecassoside failed to delay the onset of the disease, but can significantly prolong the mice’s survival time by 11.4 and 9.4 days, respectively ($P < 0.05$) [113, 114]. Also, madecassoside inhibits the production of nitric oxide (NO) (a harmless component when present in small quantities, but undesirable when secreted in large quantities), prostaglandin E2 (PGE2), and additional inflammatory factors in RAW264.7 macrophage cells lipopolysaccharide-induced (LPS) and collagen-induced arthritis in a rat model, which could explain its neuroprotective and anti-inflammatory effect [113].

According to a study by Sasmita et al., madecassoside (52) is introduced as a potent antineuroinflammatory agent, which is able to influence genetic and protein components that are implicated in neuroinflammation and to reduce the intracellular levels of reactive oxygen species (ROS) by 56.84% in BV2 microglia cell line, in comparison to the group stimulated only with LPS. The results of the present study suggest that madecassoside successfully and significantly regulated the gene and protein expression of inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2), signal transducr and transcription activator 1 (STAT1), and nuclear factor kappa B (NF-κB), which are all proneuroinflammatory components. In addition, madecassoside significantly increased the gene expression of the anti-inflammatory component heme oxygenase 1 (HO-1) by 175.22% compared to the LPS group, suggesting that this compound is an important ally in the treatment of neurodegenerative diseases [115].

In another study by Liu et al., in which researchers evaluated the protective effect of madecassoside (52) on the cognitive process induced by LPS and neuroinflammation in rats, it was observed that the treatment with madecassoside (120 mg/kg, i.g.) for 14 days reduced LPS-induced neurotoxicity, decreasing cognitive deficiencies and suppressing the production of inflammatory cytokines, such as interleukin 1-beta (IL-1β), tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6), through the activation of nuclear factor 2 signaling related to erythroid nuclear factor 2 (Nrf2). In addition, the treatment improved heme oxygenase (HO-1) protein levels, through the positive regulation of Nrf2 in LPS-stimulated neurotoxicity. Collectively, these results suggest that madecassoside is effective in preventing neurodegenerative diseases by improving memory functions due to its anti-inflammatory activities and activation of Keap1-Nrf2/HO-1 signaling [113].

Additional studies with madecassoside (52) extracted from Centella asiatica (CA) were also carried out involving the evaluation of its potential to inhibit the enzyme Serine Racemase (SR), an enzyme responsible for converting L-serine into D-serine, an amino acid coagonist at glutamate N-methyl-D-aspartate (NMDA) receptors, whose hyperexcitation is involved in several neurodegenerative diseases, including ALS. The authors observed that the activity of the SR enzyme was significantly inhibited in the presence of CA extract. The CA extract at a concentration of 20 μg/mL and 40 μg/mL inhibited 85% and 99% of SR activity ($P = 0.0001$), respectively. The enzyme inhibition assay indicates that madecassoside is an inhibitor of human SR. The I$C_{50}$ value for madecassoside is 26 μM, which is the lowest I$C_{50}$ among SR inhibitors reported up to date, giving this compound anti-inflammatory, neuroprotective, antiapoptotic, and antioxidative activity in animal models of ALS [116].

Ginsenosides are saponins found in the medicinal herb Panax ginseng that can be classified into three groups (Figure 8) based on structural differences: the protopanaxadiol group (55) (including Rb1, Rb2, Rb3, Rc, and Rd), the

---

**Figure 6:** Structure of emodin (49), aloe-emodin (50) quinones found in the roots of the *Rheum officinale* plant, and rapanone (51), a benzoquinone isolated from the *Myrsine* plant.
Huntington potentially effect oxide through the negative regulation of the NF-

protein of nitric oxide synthase (iNOS), in addition to being oxide production (NO), reducing the level of inducible pro-
tion of reactive oxygen species (ROS), releases cytochrome c

protective effect. Besides, compared to hSOD1G93A mice of the same age, those treated with G-Re showed a significant reduction in the expression of proin-
flamatory proteins, like the CD14 protein and TNF-α related to the TLR4 signaling pathway. G-Re administration also led to a decrease in phospho-p38 protein levels related to cell death and had an antioxidant effect by reducing the expression of HO-1. These results suggest that ginsenoside-Re has a potent antineuroinflammatory effect on ALS, inhibiting the TLR4 pathway.

Astragaloside IV (AST-IV) (54) is a small saponin and the main active component in Astragalus membranaceus, holding anti-inflammatory, antiviral, antiaging, immunomodulatory, and neuroprotective effects. The neuroprotective effect of this compound was observed in neural microglia cells, in which the presence of AST-IV in the concentration of 1 to 5 μmol/L protected the microglia from death caused by LPS and negatively regulated the release of proinflammatory mediators, including interleukin IL-1β, IL-6, tumor necrosis factor α (TNF-α), and nitric oxide, as well as the expression of Toll-like 4 receptors (TLR4), MyD88, and nuclear factor κB (NF-κB) of these cells. These results indicate that AST-IV exerts an anti-inflammatory effect on microglia, possibly by inhibiting the TLR4/NF-κB signaling pathways and protects neurons from microglia-mediated cell death by converting the inflammatory M1 microglia into a M2 anti-inflammatory phenotype, indicating the potential of this compound for the treatment of neurodegenerative diseases [120].

The evidence of possible beneficial effects during in vitro and in vivo studies, shown in the studies above, is a starting point for the achievement of new therapeutic alternatives in the treatment of ALS. However, it is important to note that such studies demonstrate a lack of methodological standard-ization of the samples used, ranging from commercially obtained saponins [113, 117, 120, 124] to plant extracts [116]. The lack of standardization of the samples can influence the reproducibility of the results obtained in these initial tests.

2.10. Methylxanthines. Methylated xanthines (methylxan-
thines) are heterocyclic organic compounds that are
methylated derivatives of xanthine, therefore comprising coupled rings of pyrimidinedione and imidazole. They are present in almost 100 species of 13 orders from the plant kingdom, including tea (*Camellia sinensis* L.), coffee (*Coffeea* sp.), and cocoa (*Theobroma cacao* L.), being normally included in the daily human diet in many drinks and foods extremely common, such as coffee, tea, cocoa, yerba mate, and cola. Caffeine (60), theophylline (61), and theobromine (62) (Figure 9) are the main methylxanthines available from natural sources [125, 126].

Methylxanthines have been widely used as therapeutic agents, in a range of medicinal fields, such as CNS stimulants, bronchodilators, coronary dilators, diuretics, anticancer adjuvant treatments, and, more recently, they have been suggested with a potential beneficial health effect in the treatment of neurodegenerative diseases, cardioprotection, diabetes, and fertility [126].

Caffeine is a methylxanthine that nonselectively antagonizes adenosine receptors and is the most widely used psychoactive substance in the world. Its chronic consumption has proven to be protective against neurodegenerative diseases, such as Parkinson [127], Alzheimer [128], and ALS [129]. For many years, it was believed that caffeine consumption could be associated with an increased risk of neurodegenerative diseases. However, Fondell and colleagues [129] performed a longitudinal analysis based on more than 1,010,000 men and women in five large cohort studies, in which they evaluated the association between caffeine, coffee, and tea consumption and ALS risk. The results showed that a total of 1,279 cases of ALS were documented during an average of 18 years of follow-up. Caffeine intake was not associated with the risk of ALS; the combined multivariate adjusted risk (RR) ratio was 0.96 (95% CI 0.81-1.16). Similarly, neither coffee nor tea has been associated with ALS risk. Therefore, the results of this large study did not demonstrate any associations of caffeine or caffeine drinks with the risk of ALS [130, 131].

The data found by Fondell and collaborators [129] reaffirm the results obtained by Herden and Weissert [132] when investigating in 377 patients with newly diagnosed ALS the relationship between coffee consumption and ALS risk in which they evidenced an inverse correlation between the consumption of coffee and the risk of disease.

Onatibia-Astibia et al. and Sonsalla et al. [125, 127] report that caffeine consumption improves cognitive function, prevents neurodegeneration, and restores neuronal plasticity and mitochondrial production in middle-aged rats and in the APPsw mouse model of Alzheimer’s disease.
Regarding ALS, caffeine is believed to be neuroprotective, antagonizing A2A adenosine receptors in the brain and thus protecting motor neurons from excitotoxicity [128, 129]. In this sense, Monteiro et al. [126], Kolahdouzan and Hamadeh [130], and Herden and Weisert [132] also reinforce the beneficial effects of caffeine consumption in improving motor activity in the context of neurodegenerative diseases through mechanisms of neuroprotection and neurorestoration by trophic proteins, suggesting that caffeine is a promising compound for the treatment of neurodegenerative diseases.

Caffeine is the most studied methylxanthine concerning its effect on neurodegenerative diseases. According to the studies with patients reported above, the consumption of caffeine has shown a protective effect in patients with ALS. On the other hand, there is a lack of evidence on the neuroprotective mechanism of action of this compound, and it is necessary to expand research in this area, using *in silico*, *in vitro*, and *in vivo* experiments, not only to elucidate the effect of caffeine on neurodegenerative diseases, but also to investigate new methylxanthines that may show a potential effect on these diseases. So these structures can be explored for the design of new compounds that may be more promising, facilitating the understanding of their possible mechanisms of action.

### 2.11. Glucosinolates

Glucosinolates are abundant compounds in the *Moringa* species, mainly in the *Moringa oleifera*, having been reported to have anti-inflammatory, antioxidant, anticancer, and antiangiogenic activities. The most abundant glucosinolate present in the species is 4-O-(α-L-rhamnopyranosyl)-benzyl glucosinolate, also known as glucomorinign (GMG) (63). Glucosinolates and related hydrolytic products, isothiocyanates (ITCs) (64), have attracted researchers due to their neuroprotective effect [133–136]. ITCs are phytochemicals containing sulfur and nitrogen obtained from glucosinolates after myrosinase action. Myrosinase-catalyzed hydrolysis at neutral pH of GMG releases the biologically active compound 4-((α-L-rhamnosyl)-benzylthiocyanate (GMG-ITC) (65) (Figure 10) [135, 136].

Many studies have revealed the benefits of consuming vegetables from *Brassicaceae* and *moringaceae*, which are the main sources of ITCs. These compounds are considered to contribute to the massive reduction of risk for the development of neurodegenerative diseases, due to their antiamyloidogenic, antioxidant, and anti-inflammatory properties. The preventative and treatment capacity of ITCs for NDDs is being extensively explored over the last years [135].

In this sense, Jaafaru and collaborators [137] evaluated the neuroprotective activity of GMG-ITC (65) by eliminating ROS in SH-SY5Y neuroblastoma cells (ATCC® CRL-2266™), observing that the presence of GMG-ITC (1.25 μg/mL) before the development of the oxidative stress condition decreased the expression of cyt-c (cytochrome C), p53 (also called TP53 gene and tumor protein p53 gene), Apaf-1 (apoptosis-activating factor 1), Bax (BCL-2-associated protein X), CASP3, CASP8, and CASP9 (proteins involved in the caspase pathway) with simultaneous positive regulation of the Bcl-2 gene (B cell lymphoma protein 2) in the mitochondrial apoptotic signaling pathway. In view of these results, the authors suggest that pretreatment with GMG-ITC can relieve the condition of oxidative stress in neuronal cells, reducing the level of ROS production and protecting cells against apoptosis through possible neurodegenerative pathways of disease [137].

In another study, Galuppo et al. [136] evaluated the therapeutic efficacy of GMG-ITC against ALS *in vivo* using SOD1tg mice, which physiologically develop SOD1G93A at around 16 weeks of age and can be considered a genetic model of the disease. The rats were treated once a day with GMG (10 mg/kg) bioactivated with myrosinase (20 μL/rat) by intraperitoneal injection for two weeks before the onset of the disease, and the treatment was prolonged for another two weeks before sacrifice. The results showed statistically significant differences between mice treated and untreated with GMG-IT (P = 0.003), demonstrating that the administration of GMG-IT was able to delay the onset of the disease for approximately two weeks, probably due to its immunomodulatory, anti-inflammatory, antioxidant, and antiapoptotic effects, suggesting that this compound could be a potential drug for the treatment of this disease.

Glucosinolates have been extensively studied in recent years due to their anti-inflammatory and antioxidant potential. However, few studies in the literature report their action on neurodegenerative diseases, such as ALS. Preliminary studies in both cells and animals show neuroprotective effects of these compounds, but the mechanism of action and the extent of the effects have yet to be further investigated in more robust preclinical and clinical studies.

### 2.12. Fatty Acids

The growing amount of researches involving neurodegenerative diseases shows that neurons are particularly vulnerable to oxidative damage due to their high content of polyunsaturated fatty acids in the membranes, high oxygen consumption, and weak antioxidant defense [138]. Fatty acids are essential lipid molecules to support the structural integrity of cell membranes, providing energy and assisting in signaling pathways. Studies show that a higher intake of polyunsaturated fatty acids ω3, considered neuroprotectives, was associated with a reduced risk of ASL [139].
On the other hand, Boumil et al. estimated the impact of omega-3 (Ω-3) (66) and omega-6 (Ω-6) (67) (Figure 11) in the function of the motor neuron in mice expressing the mutant human superoxide dismutase-1 (SOD1). The authors noted that supplementation with Ω-3 and Ω-6 equivalents hastened the pathology and death of motor neurons; however, 10x Ω-6 with no change in Ω-3 (1 mg/kg) significantly delayed pathology in motor neurons, including preservation of minor motor neuron function during the terminal stage, suggesting that a critical balance of Ω-6 and Ω-3 may temporarily preserve motor neuron function during the terminal stages of ALS, which could provide a substantial improvement in the quality of life of the affected individuals [140].

Assessing the therapeutic potential of fatty acids for the treatment of ALS, Tefera and collaborators [141] observed the effects of triheptanoin fatty acid (68) (Figure 11), a heptanoate triglyceride, in the treatment of mice that overexpress the SOD1G93A human gene mutant. They observed that rats fed the SF11-028 diet (composed of ingredients typical of other rat diets), modified with 35% oral triheptanoin, starting at P35 (35th day), showed attenuation in the loss of motor neurons at 70-day old by 33%. This result, combined with the pressure strength of the hind limbs, which demonstrated a delay in the loss of strength in hSOD1G93A mice treated with triheptanoin, suggests that this compound delays the loss of motor neurons and the appearance of motor symptoms in mice.

According to Días-Amarilla et al., nitro-fatty acids (NO$_2$-OA) subcutaneously. It was observed that NO$_2$-OA significantly improved the grip strength and performance on rotarod (also called rotating bar that assesses motor coordination and balance) compared to animals treated with vehicle or oleic acid (AO), suggesting NO$_2$-OA as a promising therapeutic compound [143].

Another fatty acid of importance in ALS is docosahexaenoic acid (DHA) (69) (Figure 11), an essential fatty acid that modulates the main functions of the nervous system, including neuroinflammation, and regulation of pre- and postsynaptic membrane formation, being reduced in patients with amyotrophic lateral sclerosis and preclinical murine models [144]. Based on this information, Torres et al. [144] performed dietary supplementation of DHA in a murine model fASL B6SJL-Tg(SOD1*G93A), in which they observed that a diet rich in DHA significantly increases the survival of male rats by 7% (average of 10 days over 130 days of life expectancy) and delays motor dysfunction (based on stride length) and loss of weight associated with ALS transgene (P < 0.01).

Also, DHA supplementation led to an increase in the profile of anti-inflammatory fatty acids (P < 0.01), a lower concentration of circulating proinflammatory such as the cytokine TNF-α (P < 0.001 in males), reduced immunoreactivity to markers of oxidative DNA damage (8-oxodG) in the lumbar spinal cord (LSC), and preserved the number of motor neurons compared to untreated. The literature also suggests the antioxidant action of fatty acids as the main mechanism of action.

Due to the importance of fatty acids for the structure and integrity of cell membranes, these compounds have been investigated with a potential neuroprotective effect. Studies in murine models have shown a beneficial effect obtained by the supplementation with fatty acids, such as DHA, omega-3 (Ω-3), and omega-6 (Ω-6). Nonetheless, it is important to emphasize that the amount to be supplemented is not yet well established. Some studies have suggested that the neuroprotective effect is derived from a balance between fatty acids [140]. Therefore, further research is required to establish the neuroprotective potential, the neuroprotective mechanism, and the amount of fatty acids to be used to ensure this effect.

3. Conclusions

Unfortunately, there is still no effective and/or curative treatment for the disease, and the few drugs on the market are
intended to only slow the progress of the disease. Among the most promising treatment alternatives, the effectiveness of antioxidants can be highlighted, since the disease is directly related to oxidative stress and cell death. In this context, the relevance of natural products with potential antioxidant action was reported in this review, emphasizing on oxygenated and nitrogenous compounds that are capable of acting in redox balance, attenuating or decreasing the impact of these effects on neuronal and motor cells. Among them, we highlight polyphenols, flavonoids, coumarins, and alkaloids as main metabolites, as well as unsaturated hydrocarbons, such as fatty acids and their esters, which are part of the diet worldwide and are considered promising alternatives. The mechanisms of action associated with the activity of these metabolites are not yet entirely elucidated, but researches point out that natural products capable of regulating redox effects are fundamental for cellular processes, maintaining an appropriate environment for metabolic activities and healthy functioning, as they present, in some cases, low colateral effects and multiple targets. Nevertheless, there are still few studies related to toxic effects, mechanisms of action, and strategies of molecular modifications using these prototypes through total synthesis or semisynthesis, which could lead to further preclinical and clinical trials, and eventual obtainment of safe and effective compounds that can improve the ALS patient’s outcome.

Conflicts of Interest
The authors declare no conflict of interests regarding the publication of this paper.

Acknowledgments
The authors acknowledge the financial support from Fundação de Amparo à Ciência e Tecnologia do Estado do Pernambuco (FACEPE), Federal University of Pernambuco (UFPE), State University of Paraíba (UEPB), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Apoio à Pesquisa do Estado da Paraíba (FAPESQ), and Pro-rectory of Post-graduate Studies (PROPESQ/PB).

References
[1] S. Parakh, D. M. Spencer, M. A. Halloran, K. Y. Soo, and J. D. Atkin, “Redox regulation in amyotrophic lateral sclerosis,” Oxidative medicine and cellular longevity, vol. 2013, 12 pages, 2013.
[2] K. Valko and L. Ciesla, Amyotrophic Lateral Sclerosis, Elsevier B.V, 2019.
[3] S. Chen, P. Sayana, X. Zhang, and W. Le, “Genetics of amyotrophic lateral sclerosis: an update,” Molecular Neurodegeneration, vol. 8, no. 1, p. 28, 2013.
[4] S. Zarei, K. Carr, L. Reiley et al., “A comprehensive review of amyotrophic lateral sclerosis,” Surgical neurology international, vol. 6, no. 1, p. 171, 2015.
[5] A. Gowland, S. Opie-Martin, K. M. Scott et al., “Predicting the future of ALS: the impact of demographic change and potential new treatments on the prevalence of ALS in the United Kingdom, 2020–2116,” Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 20, no. 3–4, pp. 264–274, 2019.
[6] L. Rechtman, L. Wagner, W. Kaye, and J. Villanacci, “Updated prevalence and demographic characteristics for ALS cases in Texas, 2009–2011,” Southern Medical Journal, vol. 108, no. 8, pp. 483–486, 2015.
[7] A. M. G. Ragagnin, S. Shadfar, M. Vidal, M. S. Jamali, and J. D. Atkin, “Motor neuron susceptibility in ALS/FTD,” Frontiers in Neuroscience, vol. 13, 2019.
[8] S. Saberi, J. E. Stauffer, D. J. Schulte, and J. Ravits, “Neuropathology of amyotrophic lateral sclerosis and its variants,” Neurologic Clinics, vol. 33, no. 4, pp. 855–876, 2015.
[9] J. W. Nieves, C. Gennings, P. Factor-Litvak et al., “Association between dietary intake and function in amyotrophic lateral sclerosis,” JAMA Neurology, vol. 73, no. 12, pp. 1425–1432, 2016.
[10] P. Courtarier, P. Corcia, G. Lautrette, M. Nicol, P.-M. Preux, and B. Marin, “Epidemiology of amyotrophic lateral sclerosis: a review of literature,” Revue Neurologique, vol. 172, no. 1, pp. 37–45, 2016.
[11] V. S. de Souza, W. B. V. de Rezende Pinto, M. A. T. Chieia, and A. S. B. Oliveira, “Clinical and genetic basis of familial amyotrophic lateral sclerosis,” Arquivos de Neuro-Psiquiatria, vol. 73, no. 12, pp. 1026–1037, 2015.
[12] M. Yusuf, M. Khan, M. A. Robaiai, and R. A. Khan, “Biomechanistic insights into the roles of oxidative stress in generating complex neurological disorders,” Biological Chemistry, vol. 399, no. 4, pp. 305–319, 2018.
[13] S. Carrera-Juliá, M. L. Moreno, C. Barrios, J. E. de la Rubia Ortí, and E. Drehmer, “Antioxidant alternatives in the treatment of amyotrophic lateral sclerosis: a comprehensive review,” *Frontiers in Physiology*, vol. 11, p. 63, 2020.

[14] S. L. Albarracin, B. Stab, Z. Casas et al., “Effects of natural antioxidants in neurodegenerative disease,” *Nutritional Neuroscience*, vol. 15, no. 1, pp. 1–9, 2013.

[15] E. Niedzielska, I. Smaga, M. Gawlik et al., “Oxidative stress in neurodegenerative diseases,” *Molecular Neurobiology*, vol. 53, no. 6, pp. 4094–4125, 2016.

[16] M. C. Kiernan, S. Vucic, B. C. Cheah et al., “Amyotrophic lateral sclerosis,” *Lancet*, vol. 377, no. 9769, pp. 942–955, 2011.

[17] R. Bhattacharya, R. A. Harvey, K. Abraham, J. Rosen, and P. Mehta, “Amyotrophic lateral sclerosis among patients with a Medicare Advantage prescription drug plan; prevalence, survival and patient characteristics,” *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, vol. 20, no. 3–4, pp. 251–259, 2019.

[18] M. Lahlou, “The Success of Natural Products in Drug Discovery,” *Pharmacology & Pharmacy*, vol. 4, no. 3, pp. 17–31, 2013.

[19] K. C. Fitzgerald, E. J. O’Regil, E. Fondell et al., “Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis: pooled results from 5 cohort studies,” *Annals of Neurology*, vol. 73, no. 2, pp. 236–245, 2013.

[20] R. N. Krishnaraj, S. S. S. Kumari, and S. S. Mukhopadhyay, “Antagonistic molecular interactions of photosynthetic pigments with molecular disease targets: a new approach to treat AD and ALS,” *Journal of Receptors and Signal Transduction*, vol. 36, no. 1, pp. 67–71, 2016.

[21] D. Ribeiro, M. Freitas, A. M. S. Silva, F. Carvalho, and E. Fernandes, “Antioxidant and pro-oxidant activities of carotenoids and their oxidation products,” *Food and Chemical Toxicology*, vol. 120, pp. 681–699, 2017.

[22] Z. Yan, Y. Zhong, Y. Duan, Q. Chen, and F. Li, “Antioxidant mechanism of tea polyphenols and its impact on health benefits,” *Animal Nutrition*, vol. 6, no. 2, pp. 115–123, 2020.

[23] S. Nabavi, M. Daglia, G. D’Antona, E. Sobarzo-Sanchez, Z. Talas, and S. Nabavi, “Natural compounds used as therapies targeting to amyotrophic lateral sclerosis,” *Current Pharmaceutical Biotechnology*, vol. 16, no. 3, pp. 211–218, 2015.

[24] M. Ur Rashid, M. Alamzvb, S. Ali et al., “The chemistry and pharmacology of alkaloids and allied nitrogen compounds from Artemisia species: a review,” *Phytotherapy Research*, vol. 33, no. 10, pp. 2661–2684, 2019.

[25] A. L. Souto, J. F. Tavares, M. S. da Silva, M. F. F. Diniz, P. F. de Athayde-Filho, and J. M. Barbosa Filho, “Anti-inflammatory activity of alkaloids: an update from 2000 to 2010,” *Molecules*, vol. 16, no. 10, pp. 8515–8534, 2011.

[26] B. Deb Nath, W. S. Singh, M. Das et al., “Role of plant alkaloids on human health: a review of biological activities,” *Materials Today Chemistry*, vol. 9, pp. 56–72, 2018.

[27] S. Bunsupa, M. Yamazaki, and K. Saito, “Lysine-derived alkaloids: overview and update on biosynthesis and medicinal applications with emphasis on quinolizidine alkaloids,” *Mini-Reviews in Medicinal Chemistry*, vol. 17, no. 12, pp. 1002–1012, 2017.

[28] A. Roy, “A review on the alkaloids an important therapeutic compound from plants,” *International Journal of Plant Biotechnology*, vol. 3, no. 2, pp. 1–9, 2017.

[29] Y. Li, R. Sattler, E. J. Yang et al., “Harmine, a natural betacaroline alkaloid, upregulates astroglial glutamate transporter expression,” *Neuropharmacology*, vol. 60, no. 7–8, pp. 1168–1175, 2011.

[30] L. A. Mohamed, S. Markandaih, S. Bonanno, P. Pasinelli, and D. Trott, “Blood–brain barrier driven pharmacoresistance in amyotrophic lateral sclerosis and challenges for effective drug therapies,” *AAPS Journal*, vol. 19, no. 6, pp. 1600–1614, 2017.

[31] D. Lopez and S. Martinez-Luis, “Marine natural products with P-glycoprotein inhibitor properties,” *Marine Drugs*, vol. 12, no. 1, pp. 525–546, 2014.

[32] A. A. Skhalyakhov, H. R. Siyukhov, and Z. T. Tazova, “Phenolic compounds and antioxidant potential of wild-growing plant materials of the North Caucasus region,” *International Journal of Engineering and Advanced Technology*, vol. 9, no. 2, pp. 5062–5071, 2019.

[33] P. Roy, S. Amdekar, A. Kumar, and V. Singh, “Preliminary study of the antioxidant properties of flowers and roots of *Pyrostegia venusta* (Ker Gawl) Miers,” *BMC Complementary and Alternative Medicine*, vol. 11, no. 1, pp. 1–8, 2011.

[34] V. Palomo, I. D. Perez, C. Gil, and A. Martinez, “The potential role of glycochen synthesis kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy,” *Current Medicinal Chemistry*, vol. 18, no. 20, pp. 3028–3034, 2011.

[35] S. Hossein, M. El-Sayed, and H. Aoshima, “Antioxidative and anti-alpha-amylase activities of four wild plants consumed by pastoral nomads in Egypt,” *Oriental Pharmacy and Experimental Medicine*, vol. 9, no. 3, pp. 217–224, 2009.

[36] B. L. Nanda, “Determination of phytochemicals and antioxidant activity of *Acorus Calamus Rhizome*,” *Journal of Drug Delivery and Therapeutics*, vol. 4, no. 6, pp. 117–121, 2014.

[37] N. Cortes, C. Castaña, E. H. Osorio, G. P. Cardona-Gomez, and E. Osorio, “*Amaryllidaceae* alkaloids as agents with protective effects against oxidative neural cell injury,” *Life Sciences*, vol. 203, pp. 54–65, 2018.

[38] F. T. Zohora, S. N. Islam, S. A. Khan, C. M. Hasan, and M. Ahsan, “Antioxidant, cytotoxic, thrombolytic and antimicrobial activity of &lt;researcher:Zanthoxylum rhesa</researcher>,” root bark with two isolated quinolone alkaloids,” *Pharmacology & Pharmacy*, vol. 10, no. 3, pp. 137–145, 2019.

[39] H. H. F. Koolen, E. S. Pral, S. C. Alphana, and M. Ahsan, “Physicochemical characterization, and antiprotostosomal and antioxidant alkaloids from *Alternanthera littoralis*,” *Phytochemistry Letters*, vol. 134, pp. 106–113, 2017.

[40] C. B. Azavedo, M. Roxo, C. M. Borges et al., “Antiprotozoal and antioxidant alkaloids from *Alternanthera littoralis*,” *Phytochemistry*, vol. 65, pp. 39–45, 2013.

[41] A. K. O. Aldulaimi, S. S. Aziz, Y. M. Bakri et al., “Two New isoquinoline alkaloids from the bark of *Alphonsea cylindrica King* and their antioxidant activity,” *Phytochemistry Letters*, vol. 29, pp. 110–114, 2019.

[42] A. Mundaragi, D. Thangadurai, K. A. A. Appaiah, C. J. Dhanalakshmi, and J. Sangeetha, “Physicochemical characterization, antioxidant potential and sensory quality of wine from wild edible fruits of *Flacourtia montana* J. Graham,” *Brazilian Archives of Biology and Technology*, vol. 62, pp. 1–12, 2019.

[43] C. O. Akoto, A. A. Acheampong, P. D. Tagbor, and K. Bortey, “Determination of the antimicrobial and antioxidant activities of the leaf extracts of *Griffonia simplicifolia*,” *Journal of*
Pharmcognosy and Phytochemistry, vol. 9, no. 2, pp. 537–545, 2020.

[44] A. Sikandar, M. Zhang, Y. Wang et al., “Mycochemical screening and analysis, antioxidant activity, and biochemical composition of fermentation strain Snf1216 (Penicillium chrysogenum),” Journal of Analytical Methods in Chemistry, vol. 2020, Article ID 3073906, 8 pages, 2020.

[45] M. A. Rahman, M. R. Rahman, T. Zaman et al., “Emerging potential of naturally occurring autophagy modulator against neurodegeneration,” Current Pharmaceutical Design, vol. 26, no. 7, pp. 4–6, 2020.

[46] D. J. McNally, K. Wurms, C. Labbé, and R. R. Bélanger, “A standardized methodology for the study of induced glycosylated plant phenolics,” Canadian Journal of Plant Pathology, vol. 24, no. 4, pp. 429–436, 2002.

[47] T. B. Soares, L. Loureiro, A. Carvalho et al., “Lipid nanocarriers loaded with natural compounds: potential new therapies for age related neurodegenerative diseases?” Progress in Neurobiology, vol. 168, pp. 21–41, 2018.

[48] L. Wen, Y. Tan, S. Dai et al., “VEGF-mediated tight junctions pathological fenestrination enhances doxorubicin-loaded glycolipid-like nanoparticles traversing bbb for glioblastoma-targeting therapy,” Drug Delivery, vol. 24, no. 1, pp. 1843–1855, 2017.

[49] P. G. Pietta, “Flavonoids as antioxidants,” Journal of Natural Products, vol. 63, no. 7, pp. 1035–1042, 2000.

[50] A. N. Winter, E. K. Ross, H. M. Wilkins et al., “An anthocyanin-enriched extract from strawberries delays disease onset and extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis,” Nutritional Neuroscience, vol. 21, no. 6, pp. 414–426, 2017.

[51] C. L. Bordignon Junior, V. Francescatto, A. A. Nienow, E. Calvete, and F. H. Reginatto, “Influence of the extraction solution pH on the content of anthocyanins in strawberry fruits,” Food Science and Technology, vol. 29, no. 1, pp. 183–188, 2009.

[52] M. L. Cardoso, J. P. V. Leite, and M. C. G. Peluzio, “Biological effects of anthocyanins on the atherosclerotic process,” Colombian Journal of Chemical and Pharmaceutical Sciences, vol. 40, no. 1, 2011.

[53] D. R. Sari, A. Safitri, J. R. Cairns, and F. Batchiyah, “Anti-apoptotic activity of anthocyanins has potential to inhibit caspase-3 signaling,” Journal of Tropical Life Science, vol. 10, no. 1, pp. 15–25, 2020.

[54] E. Srivivasan and R. Rajasekaran, “Comparative binding of kaempferol and kaempferide on inhibiting the aggregate formation of mutant (G85R) SOD1 protein in familial amyotrophic lateral sclerosis: a quantum chemical and molecular mechanics study,” BioFactors, vol. 44, no. 5, pp. 431–442, 2018.

[55] T. Ueda, M. Inden, K. Shirai et al., “The effects of Brazilian green propolis that contains flavonoids against mutant copper-zinc superoxide dismutase-mediated toxicity,” Scientific Reports, vol. 7, no. 1, pp. 1–11, 2017.

[56] T. H. Wang, S. Y. Wang, X. D. Wang et al., “Fisetin exerts antioxidant and neuroprotective effects in multiple mutant hSOD1 models of amyotrophic lateral sclerosis by activating ERK,” Neuroscience, vol. 379, pp. 152–166, 2018.

[57] P. Ip, P. R. Sharda, A. Cunningham, S. Chakrabarty, V. Pande, and A. Chakrabarty, “Quercitin and quercetin 3-β-d-glucoside as chemical chaperones for the A4V SOD1 ALS-causing mutant,” Protein Engineering, Design and Selection, vol. 30, no. 6, pp. 431–440, 2017.

[58] F. Jiang, S. De Silva, and J. Turnbull, “Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice,” Journal of the Neurological Sciences, vol. 180, no. 1-2, pp. 52–54, 2000.

[59] O. T. Korkmaz, N. Aytan, I. Carreras et al., “?-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis,” Neuroscience Letters, vol. 566, pp. 286–291, 2014.

[60] V. Joshi, R. Mishra, A. Upadhyay et al., “Polyphenolic flavonoid (myricetin) upregulated proteosomal degradation mechanisms: eliminates neurodegenerative proteins aggregation,” Journal of Cellular Physiology, vol. 234, no. 11, pp. 20900–20914, 2019.

[61] Y. Shimmyo, T. Kihara, A. Akaike, T. Niidome, and H. Sugimoto,”Three distinct neuroprotective functions of myricetin against glutamate-induced neuronal cell death: involvement of direct inhibition of caspase-3,” Journal of Neuroscience Research, vol. 86, no. 8, pp. 1836–1845, 2008.

[62] D. R. Sharma, W. Y. Wani, A. Sunkaria et al., “Quercetin attenuates neuronal death against aluminum-induced neurodegeneration in the rat hippocampus,” Neuroscience, vol. 324, pp. 163–176, 2016.

[63] X. Zhuang, B. Zhao, S. Liu et al., “Noncovalent interactions between superoxide dismutase and flavonoids studied by native mass spectrometry combined with molecular simulations,” Analytical Chemistry, vol. 88, no. 23, pp. 11720–11726, 2016.

[64] A. Elmann, A. Telerman, R. Ofrir, and Y. Kashman, “Glutamate toxicity to differentiated neuroblastoma N2a cells is prevented by the sesquiterpene lactone achillolide A and the flavonoid 3, 5, 4′-trihydroxy-6, 7, 3′-trimethoxylavone from Achillea fragrantissima,” Journal of Molecular Neuroscience, vol. 62, no. 1, pp. 99–105, 2017.

[65] R. Mogana, K. T. Jin, and C. Wiart,”Anti-inflammatory, anti-cholinesterase, and antioxidant potential of scopeoletin isolated fromCanarium patentinerviumMiq. (Burseraceae Kunth),” Evidence-based complementary and alternative medicine, vol. 2013, Article ID 734824, 7 pages, 2013.

[66] G. P. Kumar, T. Anand, D. Singisit, F. Khanum, and K. R. Anilakumar,”Evaluation of antioxidant and anti-fatigue properties of Trigonella foenum-gracuum L. in rats subjected to weight loaded forced swim test,” Pharmacognosy Journal, vol. 5, no. 2, pp. 66–71, 2013.

[67] S. C. Barber, A. Higginbottom, R. J. Mead, S. Barber, and P. J. Shaw,”An in vitro screening cascade to identify neuroprotective antioxidants in ALS,” Free Radical Biology and Medicine, vol. 46, no. 8, pp. 1127–1138, 2009.

[68] M. A. Hasnat, M. Pervin, and B. O. Lim,”Acetycholinesterase inhibition and in vitro and in vivo antioxidant activities of Ganoderma lucidum grown on germinated brown rice,” Molecules, vol. 18, no. 6, pp. 6663–6678, 2013.

[69] L. Li and N. P. Seeram,”Maple syrup phytochemicals include lignans, coumarins, a stilbene, and other previously unreported antioxidant phenolic compounds,” Journal of Agricultural and Food Chemistry, vol. 58, no. 22, pp. 11673–11679, 2010.

[70] E. P. Pereira, S. Braga-de-Souza, C. C. Santos et al.,”Amburana cearensis seed extracts protect PC-12 cells against toxicity induced by glutamate,” Brazilian Journal of Pharmcognosy, vol. 27, no. 2, pp. 199–205, 2017.
[71] Y. J. Moon, J. Y. Lee, M. S. Oh et al., "Inhibition of inflammation and oxidative stress by Angelica dahuricae radix extract decreases apoptotic cell death and improves functional recovery after spinal cord injury," *Journal of Neuroscience Research*, vol. 90, no. 1, pp. 243–256, 2012.

[72] S. J. Park, J. H. Yoon, Y. E. Kim, W. B. Yoon, and J. D. Kim, "In vitro antioxidant activity of the aqueous of Angelicae gigas Nakai leaves," *Korean Journal of Food Preservation*, vol. 18, no. 6, pp. 817–823, 2011.

[73] K. S. Ryu, N. D. Hong, N. J. Kim, and Y. Y. Kong, "Studies on the coumarin constituents of the root of Angelica gigas Nakai isolation of decursinol angelate and assay of decursinol angle and decursin," *Korean Journal of Pharmacognosy*, vol. 21, no. 1, pp. 64–68, 1990.

[74] Y. Song, L. Pan, W. Li et al., "Natural neuro-inflammatory inhibitors from Caragana turfanensis," *Bioorganic & Medicinal Chemistry Letters*, vol. 27, no. 20, pp. 4765–4769, 2017.

[75] A. M. Morgan, J. H. Kim, H. W. Lee et al., "Phytochemical constituents from the aerial part of Drosaria israelis Asch.," *Natural Product Sciences*, vol. 21, pp. 6–13, 2015.

[76] M. V. Krishnapriya, T. Sumathi, A. Chinnasamy, G. Balakrishnan, and P. Renjith, "Comparative analysis of potentiality of esculin and hinokitol (B-thujaplicin) as anti-parkinsonism drugs: a pilot in silico study," *International Journal of Pharmacy and Pharmaceutical Sciences*, vol. 9, no. 1, pp. 108–115, 2017.

[77] M. Nakamura, T. Suzuki, M. Takagi, H. Tamura, and T. Masuda, "Stimulation of phosphorylation of ERK and CREB by phellopterin and auraptene isolated from Citrus junos," *Natural product communications*, vol. 9, no. 10, 2014.

[78] M. S. Butler, "Natural products to drugs: natural product derived compounds in clinical trials," *Natural Product Reports*, vol. 22, no. 2, pp. 162–195, 2005.

[79] B. Morrison, K. Hensley, E. P. Pioro, S. Petri, and M. Kiae, "Amyotrophic lateral sclerosis and novel therapeutic strategies," *Neurology Research International*, vol. 2012, Article ID 798028, 3 pages, 2012.

[80] F. J. B. Mendonça-Junior, M. T. Scotti, A. Nayarisseri, E. N. T. Zondegoumba, and L. Scotti, "Natural bioactive products with antioxidant properties useful in neurodegenerative diseases," *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 7151780, 2 pages, 2019.

[81] C. Casalini, M. Lodovici, C. Briani et al., "Effect of complex polyphenols and tannins from red wine (WCPT) on chemically induced oxidative DNA damage in the rat," *European Journal of Nutrition*, vol. 38, no. 4, pp. 190–195, 1999.

[82] L. Giovannelli, G. Testa, C. de Filippo, V. Cheynier, M. N. Clifford, and P. Dolaro, "Effect of complex polyphenols and tannins from red wine on DNA oxidative damage of rat colon mucosa in vivo," *European Journal of Nutrition*, vol. 39, no. 5, pp. 207–212, 2000.

[83] O. I. Aруoma, T. Bahorun, and L. S. Jen, "Neuroprotection by bioactive components in medicinal and food plant extracts," *Mutation Research*, vol. 544, no. 2-3, pp. 203–215, 2003.

[84] J. Serrano, R. Puupponen-Pimiä, A. Dauer, A. M. Aura, and F. Saura-Calixto, "Tannins: current knowledge of food sources, intake, bioavailability and biological effects," *Molecular Nutrition Food Research*, vol. 53, pp. 310–329, 2009.

[85] B. Auddy, M. Ferreira, F. Blasina et al., "Screening of antioxidant activity of three Indian medicinal plants, traditionally used for the management of neurodegenerative diseases," *Journal of Ethnopharmacology*, vol. 84, no. 2-3, pp. 131–138, 2003.

[86] A. Banerjee et al., "In vitro study of antioxidant activity of fruit," *Food Chemistry*, vol. 90, no. 4, pp. 727–733, 2005.

[87] C. A. Rice-evans, N. J. Miller, P. G. Bolwell, P. M. Bramley, and J. B. Pridham, "The relative antioxidant activities of plant derived polyphenolic flavonoids," *Free Radical Research*, vol. 22, pp. 375–383, 1995.

[88] Y. Qingming, P. Xianhui, K. Weibao et al., "Antioxidant activities of malt extract from barley (Hordeum vulgare L.) toward various oxidative stress in vitro and in vivo," *Food Chemistry*, vol. 118, no. 1, pp. 84–89, 2010.

[89] R. Mahesh, K. Nagulendran, S. Velavan, T. Ramesh, and V. Hazeena Begum, "Studies on the antioxidative and free radical scavenging activities of myrobalan (terminaliacbutebarest) throughvarious in vitro models," *Pharmacology*, vol. 2, pp. 1–11, 2007.

[90] I. Ginsburg, L. Rozenstein-Tsalkovich, E. Koren, and H. Rosenmann, "The herbal preparation Padma® 28 protects against neurotoxicity in PC12 cells," *Phytotherapy Research*, vol. 25, no. 5, pp. 740–743, 2011.

[91] C. L. Chang, C. S. Lin, and G. H. Lai, "Phytochemical characteristics, free radical scavenging activities, and neuroprotection of five medicinal plant extracts," *Evidence-Based Complementary and Alternative Medicine*, vol. 2012, Article ID 984295, 8 pages, 2012.

[92] O. Adewale, A. Onasanya, A. Fadaka et al., "In vitro antioxidant effect of aqueous extract of Solanum macrocarpon leaves in rat liver and brain," *Oxidants and Antioxidants in Medical Science*, vol. 3, no. 3, pp. 225–229, 2014.

[93] B. Hamamcioglu, F. G. Kocanci, and B. Aslim, "Phytochemical screening and evaluation of neuroprotective, anti-mutagenic and anti-genotoxic effects of Turkish endemic Glaucium acutidatum," *South African Journal of Botany*, vol. 117, pp. 232–239, 2018.

[94] P. J. Mitchell, J. C. Hanson, A. T. Quets-Nguyen, M. Bergeron, and R. C. Smith, "A quantitative method for analysis of in vitro neurite outgrowth," *Journal of Neuroscience Methods*, vol. 164, no. 2, pp. 350–362, 2007.

[95] G. P. Kumar and F. Khanum, "Neuroprotective potential of phytochemicals," *Pharmacognosy Reviews*, vol. 6, no. 12, pp. 81–90, 2012.

[96] X. Jin, M. Y. Liiu, D. F. Zhang et al., "Natural products as a potential modulator of microglial polarization in neurodegenerative diseases," *Pharmacological Research*, vol. 145, p. 104253, 2019.

[97] D. Li, D. Liu, M. Lv, P. Gao, and X. Liu, "Isolation of triterpenoid saponins from Medicago sativa L. with neuroprotective activities," *Bioorganic & Medicinal Chemistry Letters*, vol. 30, no. 4, p. 126956, 2020.

[98] M. Kiae, K. Kipiani, S. Petri, J. Chen, N. Y. Calingasan, and T. Calingasan, "Tannins: current knowledge of food sources, intake, bioavailability and biological effects of complex polyphenols and tannins from red wine on DNA oxidative damage of rat colon mucosa in vivo," *European Journal of Nutrition*, vol. 39, no. 5, pp. 207–212, 2000.

[99] O. I. Aruoma, T. Bahorun, and L. S. Jen, "Neuroprotection by bioactive components in medicinal and food plant extracts," *Mutation Research*, vol. 544, no. 2-3, pp. 203–215, 2003.

[100] J. Lee, K. Song, E. Huh, M. S. Oh, and Y. S. Kim, "Neuroprotection against 6-OHDA toxicity in PC12 cells and mice..."
through the Nrf2 pathway by a sesquiterpenoid from *Tussilago farfara*, *Redox Biology*, vol. 18, pp. 6–15, 2018.

[101] D. E. Sok, H. Cui, and M. Kim, “Isolation and Bioactivities of furfuran type lignan compounds from edible plants,” *Recent Patents on Food, Nutrition & Agriculture*, vol. 1, no. 1, pp. 87–95, 2009.

[102] L. Tavares, G. J. McDougall, S. Fortalezas, D. Stewart, R. B. Ferreira, and C. N. Santos, “The neuroprotective potential of phenolic-enriched fractions from four *Juniperus* species found in Portugal,” *Food Chemistry*, vol. 135, no. 2, pp. 562–570, 2012.

[103] C. Wiart, Chapter 3 – Phenolics, Lead Compounds from Medicinal Plants for the Treatment of Neurodegenerative Diseases, 2014.

[104] V. Laharie-Collins, J. Bourival, M. Plouffe, J. Carange, and M. G. Martinoli, “Sesamin modulates tyrosine hydroxylase, superoxide dismutase, catalase, inducible NO synthase and interleukin-6 expression in dopaminergic cells under MPP+ induced oxidative stress,” *Oxidative Medicine and Cellular Longevity*, vol. 1, Article ID 875974, 9 pages, 2008.

[105] R. Q. Mei, Y. H. Wang, G. H. du, G. M. Liu, L. Zhang, and Y. X. Cheng, “Antioxidant lignans from the fruits of *Broussonetia papyrifera*,” *Journal Natural Products*, vol. 72, no. 4, pp. 621–625, 2009.

[106] S. Shimoyoshi, D. Takemoto, Y. Ono et al., “Sesame lignans suppress age-related cognitive decline in senescence-accelerated mice,” *Nutrients*, vol. 11, no. 7, p. 1582, 2019.

[107] H. Erlank, A. Elmann, R. Kohen, and J. Kanner, “Polyphenols activate Nrf2 in astrocytes via H₂O₂, semiquinones, and quinones,” *Free Radical Biology and Medicine*, vol. 51, no. 12, pp. 2319–2327, 2011.

[108] M. Iranshahy, M. Iranshahi, S. R. Aftahi, and G. Karimi, “The role of nuclear factor erythroid 2-related factor 2 in hepatoprotective activity of natural products: a review,” *Food and Chemical Toxicology*, vol. 120, pp. 261–276, 2018.

[109] K. Lu, C. Zhang, W. Wu, M. Zhou, Y. Tang, and Y. Peng, “Rhubarb extract has a protective role against radiation-induced brain injury and neuronal cell apoptosis,” *Molecular Medicine Reports*, vol. 12, no. 2, pp. 2689–2694, 2015.

[110] K. de la Vega-Hernández, M. Antuch, O. Cuesta-Rubio, Y. Núñez-Figueroed, and G. L. Pardo-Andreu, “Discerning the antioxidant mechanism of rapanone: a naturally occurring benzoquinone with iron complexing and radical scavenging activities,” *Journal of Inorganic Biochemistry*, vol. 170, pp. 134–147, 2017.

[111] S. M. Astuti, A. M. Mimi Sakinah, B. M. Retno Andayani, and A. Risch, “Determination of saponin compound from *Ammi* cordifolia (Ten) Steenis plant (binahong) to potential treatment for several diseases,” *Journal of Agricultural Science*, vol. 3, no. 4, 2011.

[112] L. Ravi, V. Manasi, and L. B. Praveena, “Antibacterial and antioxidant activity of saponin from abutilon indicum leaves,” *Asian Journal of Pharmaceutcal and Clinical Research*, vol. 9, no. 9, pp. 344–347, 2016.

[113] S. Liu, G. Li, H. Tang et al., “Madecassoside ameliorates lipopolysaccharide-induced neurotoxicity in rats by activating the Nrf2-HO⁻¹ pathway,” *Neuroscience Letters*, vol. 709, p. 134386, 2019.

[114] X. Zhang, Y. L. Hong, D. S. Xu et al., “A review of experimental research on herbal compounds in amyotrophic lateral sclerosis,” *Phytotherapy Research*, vol. 28, no. 1, pp. 9–21, 2014.

[115] A. O. Sasmita, A. P. K. Ling, K. G. L. Voon, R. Y. Koh, and Y. P. Wong, “Madecassoside activates antineuroinflammatory mechanisms by inhibiting lipopolysaccharide-induced microglial inflammation,” *International Journal of Molecular Medicine*, vol. 41, no. 5, pp. 3033–3040, 2018.

[116] K. Rani, M. Tyagi, M. Mazumder et al., “Accelerated identification of serine racemase inhibitor from Centella asiatica,” *Scientific Reports*, vol. 10, no. 4640, pp. 1–12, 2020.

[117] M. Cai and E. J. Yang, “Ginsenoside Re attenuates neuroinflammation in a symptomatic ALS animal model,” *The American Journal of Chinese Medicine*, vol. 44, no. 2, pp. 401–413, 2016.

[118] G. Ratheesh, L. Tian, J. R. Venugopal et al., “Role of medicinal plants in neurodegenerative diseases,” *Biomanuf Reviews*, vol. 2, no. 1, pp. 1–16, 2017.

[119] Z. A. Ratan, M. F. Haider, Y. H. Hong et al., “Pharmacological potential of ginseng and its major component ginsenosides,” *Journal of Ginseng Research*, pp. 1–36, 2020.

[120] J. Yu, M. Guo, Y. Li et al., “Astragaloside IV protects neurons from microglia-mediated cell damage through promoting microglia polarization,” *Folia Neuropathologica*, vol. 57, no. 2, pp. 170–181, 2019.

[121] A. Sun, X. Xu, J. Lin, X. Cui, and R. Xu, “Neuroprotection by saponins,” *Phytotherapy Research*, vol. 29, no. 2, pp. 187–200, 2014.

[122] X. C. Chen, Y. G. Zhu, L. A. Zhu et al., “Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress,” *European Journal of Pharmacology*, vol. 473, no. 1, pp. 1–7, 2003.

[123] Q. Liu, J. P. Kou, and B. Y. Yu, “Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-κB activation,” *Neurochemistry International*, vol. 58, no. 1, pp. 119–125, 2011.

[124] S. Zoccolella, A. Santamato, and P. Lamberti, “Current and emerging treatments for amyotrophic lateral sclerosis,” *Neuropsychiatric Disease and Treatment*, vol. 5, pp. 577–595, 2009.

[125] A. Onatibia-Astibia, R. Franco, and E. Martínez-Pinilla, “Health benefits of methyl xanthines in neurodegenerative diseases,” *Molecular Nutrition & Food Research*, vol. 61, no. 6, pp. 1–47, 2017.

[126] J. Monteiro, M. G. Alves, P. F. Oliveira, and B. M. Silva, “Pharmacological potential of methylxanthines: retrospective analysis and future expectations,” *Critical Reviews in Food Science and Nutrition*, vol. 59, no. 16, pp. 2597–2625, 2019.

[127] P. K. Sonsalla, L. Y. Wong, S. L. Harris et al., “Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson’s disease,” *Experimental Neurology*, vol. 234, no. 2, pp. 482–487, 2012.

[128] N. Dragicevic, V. Delic, C. Cao et al., “Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer’s mice and cells,” *Neuropsychopharmacology*, vol. 63, no. 8, pp. 1368–1379, 2012.

[129] E. Fondell, E. I. J. O’Reilly, K. C. Fitzgerald et al., “Intakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: results from five cohort studies,” *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, vol. 16, no. 5–6, pp. 366–371, 2015.

[130] M. K. Olahdouzan and M. J. Hamadheh, “The neuroprotective effects of caffeine in neurodegenerative diseases,” *CNS Neuroscience and Therapeutics*, vol. 23, no. 4, pp. 272–290, 2017.
L. Herden and R. Weissert, "The impact of coffee and caffeine on multiple sclerosis compared to other neurodegenerative diseases," *Frontiers in Nutrition*, vol. 5, no. 133, pp. 1–12, 2018.

E. Beghi, E. Pupillo, P. Messina et al., "Coffee and amyotrophic lateral sclerosis: a possible preventive role," *American Journal of Epidemiology*, vol. 174, no. 9, pp. 1002–1008, 2011.

N. Z. B. Rani, K. Husain, and E. Kumolosasi, "Moringa genus: a review of phytochemistry and pharmacology," *Frontiers in Pharmacology*, vol. 9, no. 108, pp. 1–26, 2018.

O. O. Igado and J. O. Olopade, "A review on the possible neuroprotective effects of Moringa oleifera," *Nigerian Journal of Physiological Sciences*, vol. 31, no. 2, pp. 183–187, 2016.

M. S. Jaafaru, N. A. Abd Karim, M. E. Enas, P. Rollin, E. Mazzon, and A. F. Abdull Razis, "Protective effect of glucosinolates hydrolytic products in neurodegenerative diseases (NDDs)," *Nutrients*, vol. 10, no. 580, pp. 1–15, 2018.

M. Galuppo, S. Giacoppo, R. Iori, G. R. de Nicola, P. Bramanti, and E. Mazzon, "Administration of 4-(α-L-Rhamnosyloxy)-benzyl isothiocyanate delays disease phenotype in SOD1G93ARats: a transgenic model of amyotrophic lateral sclerosis," *BioMed Research International*, vol. 2015, Article ID 259417, 12 pages, 2015.

M. S. Jaafaru, N. Nordin, R. Rosli et al., "Prospective role of mitochondrial apoptotic pathway in mediating GMG-ITC to reduce cytotoxicity in H2O2-induced oxidative stress in differentiated SH-SY5Y cells," *Biomedicine and Pharmacotherapy*, vol. 119, p. 109445, 2019.

Z. Liu, T. Zhou, A. C. Ziegler, P. Dimitrion, and L. Zuo, "Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications," *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 2525967, 11 pages, 2017.

J. L. G. Aguiar, "Lipid biomarkers for amyotrophic lateral sclerosis," *Frontiers in Neurology*, vol. 10, no. 284, pp. 1–6, 2019.

E. F. Boumil, R. B. Vohnoutka, Y. Liu, S. Lee, and T. B. Shea, "Omega-3 hastens and omega-6 delays the progression of neuropathology in a murine model of familial ALS," *The Open Neurology Journal*, vol. 11, no. 1, pp. 84–91, 2017.

T. W. Tefera, Y. Wong, M. E. Barkl-Luke et al., "Triheptanoin protects motor neurons and delays the onset of motor symptoms in a mouse model of amyotrophic lateral sclerosis," *PLoS One*, vol. 11, no. 8, pp. 1–24, 2016.

P. Diaz-Amarilla, E. Miquel, A. Trostchansky et al., "Electrophilic nitro-fatty acids prevent astrocyte-mediated toxicity to motor neurons in a cell model of familial amyotrophic lateral sclerosis via nuclear factor erythroid 2-related factor activation," *Free Radical Biology and Medicine*, vol. 95, pp. 112–120, 2016.

A. Trostchansky, M. Mastrogiovanni, E. Miquel et al., "Profile of arachidonic acid-derived inflammatory markers and its modulation by nitro-oleic acid in an inherited model of amyotrophic lateral sclerosis," *Frontiers in Molecular Neuroscience*, vol. 11, no. 131, 2018.

P. Torres, D. Cacabelos, J. Pairada et al., "Gender-specific beneficial effects of docosahexaenoic acid dietary supplementation in G93A-SOD1 amyotrophic lateral sclerosis mice," *Neurotherapeutics*, vol. 17, no. 1, pp. 269–281, 2020.